AlphaCrest Capital Management LLC reduced its stake in shares of Envista Holdings Co. (NYSE:NVST) by 9.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 10,265 shares of the company’s stock after selling 1,035 shares during the period. AlphaCrest Capital Management LLC’s holdings in Envista were worth $444,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the stock. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Envista in the 2nd quarter valued at about $152,000. Reynders McVeigh Capital Management LLC boosted its holdings in Envista by 3.3% in the second quarter. Reynders McVeigh Capital Management LLC now owns 23,163 shares of the company’s stock valued at $1,001,000 after acquiring an additional 744 shares during the last quarter. SG Americas Securities LLC increased its position in Envista by 209.9% during the 2nd quarter. SG Americas Securities LLC now owns 21,638 shares of the company’s stock valued at $935,000 after purchasing an additional 14,656 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in Envista during the 2nd quarter valued at approximately $2,314,000. Finally, Legal & General Group Plc raised its holdings in Envista by 145.0% during the 2nd quarter. Legal & General Group Plc now owns 255,046 shares of the company’s stock worth $11,021,000 after purchasing an additional 150,956 shares during the last quarter.
In other news, SVP Mischa Reis sold 10,016 shares of the business’s stock in a transaction dated Friday, August 27th. The shares were sold at an average price of $42.50, for a total transaction of $425,680.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at $2,085,007.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Jeffrey Kappler sold 1,717 shares of Envista stock in a transaction dated Friday, July 16th. The shares were sold at an average price of $42.00, for a total value of $72,114.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,405 shares of company stock valued at $703,447. Corporate insiders own 0.82% of the company’s stock.
Envista (NYSE:NVST) last issued its earnings results on Tuesday, August 3rd. The company reported $0.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.09. Envista had a return on equity of 9.72% and a net margin of 10.84%. The company had revenue of $740.10 million during the quarter, compared to the consensus estimate of $705.75 million. On average, equities analysts predict that Envista Holdings Co. will post 1.96 earnings per share for the current year.
Several equities research analysts have recently weighed in on NVST shares. Zacks Investment Research cut shares of Envista from a “buy” rating to a “hold” rating in a research report on Wednesday, October 6th. Piper Sandler increased their price target on Envista from $45.00 to $47.00 and gave the stock a “neutral” rating in a report on Wednesday, August 4th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $43.67.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
Featured Article: Net Asset Value
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.